Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q2 2021 · 10-Q
Revenue$501.69M$501.69M+16.8% vs Q2 2020 Net Income$12.94M$12.94MN/M vs Q2 2020 EPS Diluted$0.07$0.07N/M vs Q2 2020 Operating Income$11,672,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$60,185,000+3,721.3% Margins · derivedOperating margin2.3%+11.9 pt vs Q2 2020
Net margin2.6%+9.4 pt vs Q2 2020
ended Jun 30, 2021 · filed Jul 30, 2021 · 30 d after period end